- Home
- INZY vs SCPH Comparison
INZY vs SCPH Comparison
Compare INZY & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- SCPH
- Stock Information
- Founded
- INZY 2015
- SCPH 2013
- Country
- INZY United States
- SCPH United States
- Employees
- INZY N/A
- SCPH N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- INZY Health Care
- SCPH Health Care
- Exchange
- INZY Nasdaq
- SCPH Nasdaq
- Market Cap
- INZY 188.2M
- SCPH 179.6M
- IPO Year
- INZY 2020
- SCPH 2017
- Fundamental
- Price
- INZY $1.36
- SCPH $3.28
- Analyst Decision
- INZY Strong Buy
- SCPH Strong Buy
- Analyst Count
- INZY 8
- SCPH 2
- Target Price
- INZY $17.75
- SCPH $15.00
- AVG Volume (30 Days)
- INZY 742.6K
- SCPH 436.0K
- Earning Date
- INZY 03-11-2025
- SCPH 03-12-2025
- Dividend Yield
- INZY N/A
- SCPH N/A
- EPS Growth
- INZY N/A
- SCPH N/A
- EPS
- INZY N/A
- SCPH N/A
- Revenue
- INZY N/A
- SCPH $30,278,000.00
- Revenue This Year
- INZY N/A
- SCPH $172.64
- Revenue Next Year
- INZY N/A
- SCPH $131.43
- P/E Ratio
- INZY N/A
- SCPH N/A
- Revenue Growth
- INZY N/A
- SCPH 303.87
- 52 Week Low
- INZY $1.32
- SCPH $3.08
- 52 Week High
- INZY $7.80
- SCPH $6.54
- Technical
- Relative Strength Index (RSI)
- INZY 20.27
- SCPH 41.49
- Support Level
- INZY $1.32
- SCPH $3.27
- Resistance Level
- INZY $3.18
- SCPH $3.59
- Average True Range (ATR)
- INZY 0.27
- SCPH 0.19
- MACD
- INZY -0.15
- SCPH -0.00
- Stochastic Oscillator
- INZY 2.15
- SCPH 2.08
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.